New Prognostic Markers: The Pathway from Research to Clinical Practice.
作者信息
Savage Caroline, Vickers Andrew J
出版信息
Grand rounds Urol. 2009 Aug;8(3):7-13.
Abstract
摘要
相似文献
1
New Prognostic Markers: The Pathway from Research to Clinical Practice.
Grand rounds Urol. 2009 Aug;8(3):7-13.
2
Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway.
Arab J Urol. 2012 Jun;10(2):110-7. doi: 10.1016/j.aju.2012.02.005. Epub 2012 Apr 9.
3
The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases.
J Transl Med. 2019 Aug 13;17(1):264. doi: 10.1186/s12967-019-2016-y.
4
Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.
Breast Cancer Res. 2020 Jan 31;22(1):13. doi: 10.1186/s13058-020-1250-9.
5
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Ann Oncol. 2005 Nov;16(11):1723-39. doi: 10.1093/annonc/mdi352. Epub 2005 Jun 24.
6
Prognostic factors in pulmonary metastasectomy: spotlight on molecular and radiological markers.
Eur J Cardiothorac Surg. 2014 Mar;45(3):408-16. doi: 10.1093/ejcts/ezt288. Epub 2013 May 31.
7
The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry.
Biomark Cancer. 2013 Jul 4;5:13-29. doi: 10.4137/BIC.S11475.
8
[Can biochemical markers for bone density be recommended as diagnostic and prognostic tools in osteoporosis?].
Tidsskr Nor Laegeforen. 1998 Feb 10;118(4):575-9.
9
Prognostic markers in chronic lymphocytic leukaemia.
Best Pract Res Clin Haematol. 2007 Sep;20(3):455-68. doi: 10.1016/j.beha.2007.02.001.
10
Prognostic molecular markers in cancer - quo vadis?
Histopathology. 2013 Sep;63(3):297-308. doi: 10.1111/his.12184. Epub 2013 Jul 9.
本文引用的文献
1
Polymorphism of cytochrome P450 2B6 and prostate cancer risk: a significant association in a Japanese population.
Int J Urol. 2009 Apr;16(4):364-8. doi: 10.1111/j.1442-2042.2009.02263.x.
2
The use of PCA3 in the diagnosis of prostate cancer.
Nat Rev Urol. 2009 May;6(5):255-61. doi: 10.1038/nrurol.2009.40.
3
Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.
Prostate. 2009 Aug 1;69(11):1188-94. doi: 10.1002/pros.20963.
4
Association of a new intronic polymorphism of the SOD2 gene (G1677T) with cancer.
Cell Biochem Funct. 2009 Jun;27(4):223-7. doi: 10.1002/cbf.1560.
5
Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen.
Cancer Res. 2009 May 15;69(10):4388-97. doi: 10.1158/0008-5472.CAN-08-3901. Epub 2009 Apr 28.
6
WAVE3 is associated with invasiveness in prostate cancer cells.
Urol Oncol. 2010 May-Jun;28(3):320-7. doi: 10.1016/j.urolonc.2008.12.022. Epub 2009 Apr 22.
7
Analysis of Mel-18 expression in prostate cancer tissues and correlation with clinicopathologic features.
Urol Oncol. 2011 May-Jun;29(3):244-51. doi: 10.1016/j.urolonc.2009.02.004. Epub 2009 Apr 22.
8
SALL4 is a novel diagnostic marker for testicular germ cell tumors.
Am J Surg Pathol. 2009 Jul;33(7):1065-77. doi: 10.1097/PAS.0b013e3181a13eef.
9
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility.
Proc Natl Acad Sci U S A. 2009 May 12;106(19):7933-8. doi: 10.1073/pnas.0902104106. Epub 2009 Apr 21.
10
Screening and prostate-cancer mortality in a randomized European study.
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.
Zotero 插件